Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 109.78M | 107.46M | 80.33M | 77.21M | 65.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.78M | 107.46M | 80.33M | 77.21M | 65.27M |
| Cost of Revenue | 31.79M | 37.41M | 39.51M | 40.66M | 40.13M |
| Gross Profit | 77.98M | 70.05M | 40.82M | 36.54M | 25.14M |
| SG&A Expenses | 73.00M | 73.65M | 73.63M | 72.18M | 70.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.79M | 111.07M | 113.14M | 112.84M | 110.93M |
| Operating Income | 4.98M | -3.60M | -32.81M | -35.63M | -45.66M |
| Income Before Tax | 136.92M | 129.25M | 47.24M | 40.08M | -48.35M |
| Income Tax Expenses | 22.37M | 23.35M | 17.90M | 27.05M | 9.98M |
| Earnings from Continuing Operations | 114.54 | 105.90 | 29.34 | 13.03 | -58.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 114.54M | 105.90M | 29.34M | 13.03M | -58.33M |
| EBIT | 4.98M | -3.60M | -32.81M | -35.63M | -45.66M |
| EBITDA | 6.58M | -1.98M | -31.17M | -33.96M | -43.97M |
| EPS Basic | 2.27 | 2.09 | 0.58 | 0.25 | -1.19 |
| Normalized Basic EPS | 0.20 | 0.06 | 0.59 | 0.51 | -0.56 |
| EPS Diluted | 2.21 | 2.03 | 0.56 | 0.23 | -1.19 |
| Normalized Diluted EPS | 0.22 | 0.08 | 0.58 | 0.50 | -0.56 |
| Average Basic Shares Outstanding | 202.84M | 201.27M | 199.71M | 198.23M | 196.80M |
| Average Diluted Shares Outstanding | 206.97M | 205.39M | 201.65M | 198.78M | 196.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |